drugset / Trial / NCT04468971
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Timeline
- Start
- 2020-09-29
- Primary completion
- 2021-10-22
- Completion
- 2021-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CK0801 | Cell therapy | 1e+08 cells | — |
| Subject | CK0801 | Cell therapy | 3e+08 cells | — |